Medically Reviewed by Dr. Rahul Bhargava, MBBS, MD-General Medicine, DM-Clinical Haematology | Last Updated: [22/07/2026]
Blood cancer treatment in India includes chemotherapy, bone marrow transplant (BMT), CAR-T cell therapy (NexCAR19), targeted therapy, immunotherapy, and radiation therapy. The treatment approach depends on the specific type of blood cancer — leukemia, lymphoma, or multiple myeloma — along with the stage, patient age, and overall health. India offers these treatments at 60–80% lower cost than the US or UK, with survival rates comparable to international benchmarks at leading centres like Tata Memorial Hospital, AIIMS, and Apollo.
Blood cancers account for approximately 8% of all new cancer cases in India, with an estimated 120,000 new diagnoses and over 70,000 deaths annually (GLOBOCAN, 2022). The three main types — leukemia (cancer of blood-forming cells), lymphoma (cancer of the lymphatic system), and multiple myeloma (cancer of plasma cells) — each require different treatment protocols and have significantly different prognoses. The approval of India’s first indigenous CAR-T cell therapy (NexCAR19) in October 2023 marked a turning point, making a treatment previously costing ₹3–4 crore internationally available at ₹30–40 lakh domestically.
Need a blood cancer treatment plan?
Our Blood Cancer Specialists — Meet the Doctors
MedicoExperts connects you with India’s leading hemato-oncologists and bone marrow transplant specialists. Every treatment plan is designed and supervised by a named specialist with verified credentials.
← Scroll sideways to see full details →
| Doctor | Qualification | Specialisation | Experience |
|---|---|---|---|
| Dr. Rahul Bhargava | MBBS, MD (General Medicine), DM (Clinical Haematology) | Hemato-Oncology, BMT (1,500+ transplants), first Indian doctor to perform stem cell transplants for multiple sclerosis | 20+ years |
| Dr. Vikas Dua | MBBS, MD (Pediatrics), FNB (Pediatric Hematology Oncology) | Pediatric blood cancers, ALL in children, pediatric BMT (200+ transplants), performed rare first-of-kind transplants in India | 21+ years |
| Dr. Pawan Kumar Singh | MBBS, MD (Internal Medicine), DM (Haematology) | BMT specialist — 700+ transplants (autologous, allogeneic, haplo, MUD). Adult and pediatric blood cancers, thalassemia, aplastic anaemia | 15+ years |
| Dr. Samir Shah | MBBS, MD, MRCP, MRCPath | Blood cancer, bleeding disorders, complex hematological conditions | 25+ years |
| Dr. Punit L Jain | MBBS, MD, DM (Clinical Hematology), Fellowship (Leukemia) | Leukemia (all types), multiple myeloma, lymphoma, BMT | 14+ years |
Each doctor listed above is board-certified, practising at a NABH/JCI-accredited hospital, and available for consultation through MedicoExperts. Your case is reviewed by the most appropriate specialist based on your specific blood cancer type and stage.
Recent Scientific Advancement in India
Alka Dwivedi, a graduate student at IIT Bombay, was inspired to explore the possibility of developing CAR T-cell therapy in India due to the high cost and potential side effects associated with existing treatments being tested in the US.
Alongside colleagues Rahul Purwar and Gaurav Narula, she sought to create a therapy tailored to the needs of Indian patients. Through collaboration with experts at the NIH Clinical Center, they gained valuable insights into CAR T-cell therapy.
This led to the development of NexCAR19, India’s first approved CAR-T cell therapy, which was authorized by the Central Drugs Standard Control Organization in October 2023. Clinical trials conducted in India showed promising results, with a significant reduction in cancer extent observed in a majority of patients.
Two small trials were conducted in India involving 64 people with advanced lymphoma or leukemia. The results, presented in December 2023, showed that 67% of patients experienced a significant reduction in their cancer, with about half of them having their cancer disappear completely.
Blood Cancer Treatment Options — Quick Comparison
← Scroll sideways to compare all columns →
| Treatment | Best For | How It Works | Duration | Cost in India | Typical Outcomes |
|---|---|---|---|---|---|
| Chemotherapy | Most blood cancers (first-line) | Anticancer drugs kill cancer cells. Given in cycles via IV or oral. | 3–6 months (multiple cycles) | ₹1–5 lakh per cycle | 60–90% response in early-stage leukemia/lymphoma |
| Bone Marrow Transplant (BMT) | Relapsed leukemia, high-risk lymphoma, myeloma | Replaces diseased bone marrow with healthy stem cells (autologous or allogeneic). | 4–8 weeks (+ 3–6 months recovery) | ₹15–35 lakh | 50–70% long-term survival in eligible patients |
| CAR-T Cell Therapy (NexCAR19) | Relapsed/refractory B-cell lymphoma, ALL | Patient's T-cells genetically modified to attack cancer, then reinfused. | 4–6 weeks (one-time treatment) | ₹30–40 lakh | 67–70% overall response rate in clinical trials |
| Targeted Therapy | CML, CLL, specific lymphoma subtypes | Drugs target specific proteins/genes driving cancer growth. | Ongoing (daily oral medication) | ₹10,000–₹1.5 lakh/month | 90%+ survival in CML with imatinib |
| Immunotherapy | Hodgkin lymphoma, DLBCL, relapsed cases | Checkpoint inhibitors or monoclonal antibodies boost immune response against cancer. | 6–12 months (IV infusion cycles) | ₹1–3 lakh per cycle | 65–85% response in relapsed Hodgkin lymphoma |
| Radiation Therapy | Localised lymphoma, pre-BMT conditioning | High-energy beams destroy cancer cells in targeted areas. | 2–6 weeks (daily sessions) | ₹2–5 lakh total | Often curative for early-stage Hodgkin lymphoma |
Treatment by Blood Cancer Type
Leukemia Treatment in India
Acute Lymphoblastic Leukemia (ALL) is most common in children and has one of the highest cure rates in oncology. Treatment involves intensive chemotherapy over 2–3 years, with survival rates exceeding 90% in children and 40–50% in adults. Patients who relapse may be eligible for CAR-T cell therapy (NexCAR19) or bone marrow transplant.
Acute Myeloid Leukemia (AML) requires aggressive induction chemotherapy followed by consolidation therapy. BMT is recommended for high-risk patients. Five-year survival is approximately 30–40% in adults.
Chronic Myeloid Leukemia (CML) has been transformed by targeted therapy. Imatinib and newer tyrosine kinase inhibitors achieve near-normal life expectancy. India manufactures generic imatinib at ₹8,000–15,000/month vs $8,000+ internationally.
Chronic Lymphocytic Leukemia (CLL) often requires no immediate treatment. When treatment is needed, targeted therapies like ibrutinib and venetoclax are standard.
Lymphoma Treatment in India
Hodgkin Lymphoma is one of the most curable cancers. ABVD chemotherapy achieves cure rates of 85–90% in early-stage disease. For relapsed cases, salvage chemotherapy followed by autologous BMT is standard, with checkpoint inhibitors available for further relapse.
Non-Hodgkin Lymphoma (NHL) encompasses over 60 subtypes. Aggressive DLBCL is treated with R-CHOP chemotherapy (60–70% cure rates). CAR-T therapy is approved for relapsed DLBCL with 40–50% complete response rates.
Multiple Myeloma Treatment in India
Modern myeloma treatment uses proteasome inhibitors (bortezomib), immunomodulatory drugs (lenalidomide), and monoclonal antibodies (daratumumab). Eligible patients receive induction chemotherapy followed by autologous BMT. Median survival has extended to 7–10 years with maintenance therapy.
Blood Cancer Treatment Options in India
Treatment will depend on the type of Blood Cancer, age, how fast the cancer is developing, and whether the cancer has spread to other parts of your body. Blood cancer treatment in India has massively improved over the last few decades, several types of blood cancers are now highly treatable.
Blood cancer treatment in India includes the following:
An Anticancer drug that is introduced to the body via injection into the vein or sometimes taken as a pill to kill and halt the production of cancer cells. This treatment is often carried out for several months. It can be done on an outpatient or inpatient basis depending upon diagnosis of blood cancer. Doctors use chemotherapy to treat cancer and also relieve the symptoms such as shrinking tumors that can cause pain.
Depending on the stage and type of blood cancer, chemotherapy is either given through mouth or injection. Usually, the chemotherapy is given in cycles with a treatment period followed by rest that allows the body to recover and build strength. For blood cancer treatment in India, doctors often use chemotherapy along with radiation therapy.
There are some side effects of chemotherapy depending upon the type of treatment including fatigue, nausea, and hair loss.
This type of treatment involves high-energy radiation to kill cancer cells. They may be given chemotherapy at times. They are given through injections or tablets into the vein. This treatment takes several days or months and blood cancer cells keep dying even after the therapy ends. The session will take 30 mins to 1 hour every five days a week for 7-20 weeks usually, the patient needs a 2-3 day break after 5 days to help restore the healthy cells.
Two types of radiation therapy include:
External Radiation Therapy:
This therapy uses a machine to send streams of energy into the blood cancer cells through the skin. Before the process, the patient has to undergo a simulation that measures the angle at which radiation has to be done.
Only specific areas with cancer are open to radiation while the remaining parts of the body like ovaries and testes are under the shield. Hence there are fewer chances of skin reactions in patients.
Internal Radiation Therapy:
In this therapy, the source of radiation is inside the body and it can be a liquid or a solid. During this therapy, the patient’s blood count needs close supervision since he/she might need a blood transfusion. The treatment involves damaging the DNA in cancer cells.
There are some side effects of radiation therapy like Fatigue, skin problems, decrease in blood cell count, hair loss, dizziness, variation in blood pressure, and heartbeat. The most affected areas during the treatment include the heart, kidneys, chest, head, neck, and central nervous system.
This form of treatment involves drugs that kill malignant blood cells, without harming normal cells. A potential target for this therapy would be protein present in the cancer cells. It can involve different things like blocking the cancer cells from growing and dividing, preventing the cells from living longer, or destroying the cancer cells themselves.
There are several types of target therapy available but the most common ones are monoclonal antibodies and small-molecule drugs.
Monoclonal Antibodies:
They block specific targets outside cancer cells that might be an area around cancer.
Small-Molecule Drugs:
These drugs block the process that helps cancer cells to multiply. Angiogenesis inhibitors are an example of this type of therapy that makes new blood vessels. A tumor needs blood vessels to bring its nutrients and angiogenesis starves the tumor by preventing new blood vessels from forming tissue around it.
In this treatment, healthy bone marrow is infused into your body to produce healthy blood followed by therapy to destroy malignant blood cells. This bone marrow is very rich in stem cells which help in growing in all types of blood cells including red blood cells, white blood cells, and platelets. BMT is a permanent cure and the best blood cancer treatment in India.
There are three types of bone marrow transplants for blood cancer:
1. Autologous Transplantation
It is a stage when stem cells are collected from a patient prior to chemotherapy treatment and re-introduced into the patient’s body after treatment. The high doses of chemotherapy kill the cancerous cells in the blood.
2. Allogeneic Transplantation
It is a stage when a patient receives stem cells from a related or unrelated donor.
Depending on the relation of the donor and the matching of tissue, Allogenic BMT is further classified into 3 types. They are;
a) Complete Matched Sibling Donor BMT: In this, the donor is most likely to be a brother or sister of the patient. These are often a complete match to the patient’s tissue.
b) Haplo-Identical BMT: It is a type of Allogenic BMT in which parents are usually a donor to the patient since they are a half match for their children. In cases, where a complete match is not found and the patients do not have any siblings, the expert surgeon considers the parents to be a donor and perform Haplo-identical BMT.
c) Unrelated Donor BMT: In cases, where there is no sibling and the parents are also not a match for the patient, then Un-related Donor BMT is the solution, in which a donor who is unrelated to you is made available for the transplant from the Donor Match Registry.
3. Umbilical Cord Blood Transplant
This is a type of allogeneic transplant. Right after birth, stem cells are extracted from a newborn baby’s umbilical cord. The stem cells are frozen and kept until a transplant is required. Because umbilical cord blood cells are so immature, perfect matching isn’t required. Blood counts take much longer to recover due to the lower number of stem cells.
Because most of the blood stem cells live in bone marrow, bone marrow transplants are also known as stem cell transplants in some countries. It involves harvesting bone marrow from a donor through a needle while the donor is under anesthesia.
This treatment activates the immune system to kill cancer cells. It can work directly with your body’s immune system to slow the growth of cancer cells or destroy the cancer cells. Immunotherapy treatment is carried out one or a few times a week for several weeks. In most cases, you will receive a shot of immunotherapy into a vein over the course of a few hours.
There are a few side effects of having immunotherapy depending upon the agent used and also differ from person to person.
These treatments often can cause rashes or swelling at the injection area and may cause headaches, muscle aches, fever, and weakness.
Different types of Immunotherapy include:
Cytokines:
These are proteins made by white blood cells to regulate the immune response and help to slow the growth of cancer cells. There are two types of cytokines – interferon and interleukin.
Gene Therapy:
In this approach, genetic materials are inserted into the cells to fight blood cancer using a viral vector.
Immunomodulators:
These are the substances that affect the eBay cells interacting with each other to divide and grow.
Monoclonal Antibodies:
These are lab-produced antibodies that bind to cancer cells and allow the immune system to kill the cancer cells in the blood and bone marrow.
India’s first indigenous CAR-T therapy, NexCAR19, was approved in October 2023 by CDSCO. Clinical trials involving 64 patients showed a 67% overall response rate, with approximately half achieving complete remission. Available at Tata Memorial (Mumbai), Apollo (Delhi, Mumbai), BLK-Max (Delhi), Kokilaben (Mumbai). Cost: ₹30–40 lakh — one-tenth of the US price.
Blood cancer treatment explained by renowned consultant hematologist, hemato – oncologist & Bone Marrow Transplant – Dr Puneet Jain
Why Choose India for Blood Cancer Treatment?
Blood cancer treatment in India costs 60–90% less than equivalent care in the US, UK, or Europe. A bone marrow transplant that costs $150,000–$300,000 in the US is available for ₹15–35 lakh ($18,000–$42,000) in India. CAR-T therapy through NexCAR19 costs ₹30–40 lakh vs $400,000–$500,000 internationally. This cost difference is not due to lower quality — it reflects India’s lower cost of living, competitive hospital market, and domestic pharmaceutical manufacturing.
India’s hemato-oncologists train at institutions comparable to those in the US and UK. Many hold fellowships from Memorial Sloan Kettering, MD Anderson, Fred Hutchinson, and the Royal Marsden. Tata Memorial Hospital handles more blood cancer cases than almost any centre in Asia. India performed over 3,000 bone marrow transplants in 2024, with survival rates comparable to international benchmarks.
India was the first country outside the US and Europe to develop its own CAR-T cell therapy (NexCAR19). Leading hospitals have PET-CT, flow cytometry, next-generation sequencing for molecular profiling, and fully equipped BMT isolation units. Clinical trial access for newer therapies is expanding through centres like Tata Memorial, RGCIRC, and HCG.
How MedicoExperts Supports International Patients
MedicoExperts manages the complete treatment journey for international blood cancer patients:
- Free initial consultation: Submit your medical reports online. A hemato-oncologist reviews your case and provides a treatment plan within 24-48 hours.
- Hospital and doctor selection: Based on your cancer type and stage, we recommend the most appropriate specialist and centre.
- Cost estimate: Transparent, itemised cost breakdown before you travel. No hidden charges.
- Visa assistance: Medical visa invitation letter from the treating hospital. Guidance on visa application process.
- Travel and accommodation: Airport pickup, accommodation near the hospital, local SIM card, currency exchange assistance.
- Language support: Coordinators who speak English, Hindi, Arabic, French, Swahili, etc.
- Treatment coordination: Dedicated case manager throughout your stay. All appointments, tests, and admissions pre-scheduled.
- Post-treatment follow-up: Remote consultations with your treating doctor after you return home. Report interpretation and medication guidance.
Your Treatment Journey — What to Expect Step by Step
- Step 1 — Remote Consultation (Week 1): You share your medical records (blood reports, biopsy, PET/CT scans) with MedicoExperts. A hemato-oncologist reviews your case and provides a preliminary treatment plan, estimated cost, and recommended hospital within 24-48 hours. Video consultation with the specialist is arranged if needed.
- Step 2 — Treatment Confirmation (Week 2): Once you decide to proceed, MedicoExperts arranges the medical visa invitation letter, finalises the treatment schedule, and provides an itemised cost estimate. You book travel and accommodation (we assist with both).
- Step 3 — Arrival and Diagnostic Confirmation (Days 1–5 in India): On arrival, you meet your case manager and are taken to the hospital for confirmatory testing. This may include repeat blood work, bone marrow biopsy, PET-CT scan, and molecular profiling. These tests confirm the diagnosis and may refine the treatment plan.
- Step 4 — Treatment Phase (Varies by treatment type): Chemotherapy: 3–6 months of cyclic treatment, often with outpatient visits between cycles. BMT: 4–8 weeks in hospital (pre-conditioning, transplant, and engraftment), followed by 2–3 months of close monitoring. CAR-T: 4–6 weeks total (cell collection, manufacturing, infusion, monitoring). You stay in India during active treatment with regular doctor visits.
- Step 5 — Recovery and Monitoring (2–8 weeks post-treatment): After the active treatment phase, your doctor monitors your recovery through regular blood tests and imaging. You remain in India until your specialist confirms it is safe to travel home.
- Step 6 — Return Home and Follow-Up (Ongoing): Before departure, your doctor provides a detailed discharge summary, medication plan, and follow-up schedule. MedicoExperts arranges remote consultations with your treating specialist at 1-month, 3-month, 6-month, and 12-month intervals. Blood tests and scans can be done locally and shared digitally for review.
Blood Cancer Treatment Cost in India — By Treatment and City
Treatment-wise cost comparison (India vs US):
← Scroll sideways to compare →
| Treatment | Cost in India (₹) | Cost in US ($) | Savings |
|---|---|---|---|
| Chemotherapy (per cycle) | ₹1–5 lakh | $10,000–30,000 | 70–80% |
| Bone Marrow Transplant (allogeneic) | ₹15–35 lakh | $150,000–300,000 | 75–85% |
| CAR-T Cell Therapy (NexCAR19) | ₹30–40 lakh | $400,000–500,000 | 90% |
| Targeted Therapy (monthly) | ₹10,000–₹1.5 lakh | $5,000–15,000 | 80–90% |
| Immunotherapy (per cycle) | ₹1–3 lakh | $10,000–30,000 | 70–80% |
| Radiation Therapy (full course) | ₹2–5 lakh | $30,000–80,000 | 80–90% |
City-wise cost range for complete blood cancer treatment in India:
← Scroll sideways to compare →
| City | Chemotherapy (total) | BMT | CAR-T |
|---|---|---|---|
| Mumbai | ₹5–20 lakh | ₹18–35 lakh | ₹30–40 lakh |
| Delhi/NCR | ₹5–18 lakh | ₹15–30 lakh | ₹30–40 lakh |
| Chennai | ₹4–15 lakh | ₹12–25 lakh | — |
| Bangalore | ₹5–18 lakh | ₹15–28 lakh | ₹35–45 lakh |
| Hyderabad | ₹4–15 lakh | ₹12–25 lakh | — |
| Vellore | ₹3–12 lakh | ₹10–20 lakh | — |
Note: Costs are approximate and vary by treatment protocol, hospital type, and individual factors.
Blood Cancer Survival Rates in India
← Scroll sideways to see full details →
| Blood Cancer Type | 5-Year Survival Rate | Notes |
|---|---|---|
| ALL (Children) | 85–90% | One of the most curable cancers when treated promptly |
| ALL (Adults) | 40–50% | Lower than children; CAR-T improving outcomes in relapsed cases |
| AML | 30–40% | Varies significantly by age and molecular subtype |
| CML | 90%+ | Transformed by imatinib; near-normal life expectancy with treatment |
| CLL | 80–85% | Often indolent; many patients live 10–15+ years |
| Hodgkin Lymphoma | 85–90% | Among the most curable cancers overall |
| DLBCL (NHL) | 60–70% | Most common aggressive NHL; R-CHOP is standard treatment |
| Multiple Myeloma | 55–60% | Not curable but increasingly manageable; median survival 7–10 years |
When to See a Blood Cancer Specialist
Seek immediate consultation with a hemato-oncologist if you experience: persistent unexplained fatigue lasting more than 2 weeks, frequent infections, unexplained bruising or bleeding, painless swelling of lymph nodes, unexplained weight loss exceeding 5% in 6 months, drenching night sweats, bone pain without injury, or persistent fever without clear cause.
Seek emergency care if you experience high fever with very low white blood cell count (neutropenic fever), uncontrolled bleeding, severe shortness of breath, or sudden confusion.
Key Takeaways
Blood cancer treatment in India offers world-class outcomes at a fraction of the international cost. The key points: chemotherapy, BMT, CAR-T, targeted therapy, immunotherapy, and radiation are all available at accredited centres. India’s NexCAR19 makes CAR-T therapy accessible at one-tenth the US cost. Survival rates at leading Indian centres are comparable to international benchmarks. MedicoExperts connects patients with named specialists and manages the entire treatment journey from first consultation to post-treatment follow-up.
If you or a family member has been diagnosed with blood cancer, a second opinion from a specialised hemato-oncologist can clarify the treatment path and potentially identify options not initially considered.
Frequently Asked Questions (FAQs):
Q1. Is blood cancer curable?
Many blood cancers are curable, particularly Hodgkin lymphoma (85–90% cure rate), childhood ALL (85–90%), and CML (near-normal life expectancy with targeted therapy). Other types like AML and DLBCL have cure rates of 30–70% depending on subtype and stage. Multiple myeloma is not curable but increasingly manageable with modern treatments extending survival to 7–10+ years.
Q2. What is the best treatment for blood cancer in India?
The best treatment depends on the type and stage. Chemotherapy is first-line for most types. BMT is recommended for high-risk or relapsed cases. CAR-T (NexCAR19) is available for relapsed B-cell lymphoma and ALL. Targeted therapy has transformed CML. Your hemato-oncologist determines the optimal approach based on molecular testing and staging.
Q3. How much does blood cancer treatment cost in India?
Costs range from ₹5–15 lakh for chemotherapy to ₹15–35 lakh for BMT and ₹30–40 lakh for CAR-T. These are 60–90% lower than the US or UK. Government hospitals offer subsidised rates. MedicoExperts provides a transparent, itemised cost estimate before treatment begins.
Q4. What is the survival rate for blood cancer?
Survival varies by type: Hodgkin lymphoma and childhood ALL have 85–90% five-year survival. CML achieves near-normal life expectancy. AML survival is 30–40% in adults. Myeloma median survival is 7–10 years. Early diagnosis and appropriate treatment are the strongest predictors.
Q5. How long does blood cancer treatment take in India?
Duration varies: chemotherapy takes 3–6 months in cycles, BMT requires 4–8 weeks in hospital plus 3–6 months recovery, CAR-T is a one-time infusion with 4–6 weeks total. Most international patients stay in India for 2–6 months depending on treatment. MedicoExperts coordinates the entire timeline.
Next in Blood Cancer
Author Bio:
Dr. Yashashree Joshi – MBBS, MD (Philippines)
Dr. Yashashree Joshi, MD, is a globally-trained oncologist with a robust academic background and extensive experience in pioneering cancer treatments. Dedicated to patient-centered care, she continually integrates the latest advancements in oncology to provide her patients with innovative and personalized treatment plans.
Content Medically Reviewed By MedicoExperts Editorial & Clinically Review Board
- GLOBOCAN 2022. India Cancer Fact Sheet. International Agency for Research on Cancer. WHO.
- NCI. NexCAR19 CAR T-Cell Therapy India NCI Collaboration. cancer.gov. 2024.
- PMC. India’s Homegrown CAR-T Cell Therapy. PMC11620990. 2024.
- Tata Memorial Centre Annual Report 2024. Haemato-Oncology Division.
- NCCN Guidelines: Acute Lymphoblastic Leukemia. Version 2.2024.
- WHO Classification of Tumours: Haematopoietic and Lymphoid Tissues. 5th Ed. 2022.
- Kumar L et al. Multiple Myeloma in India. Indian J Hematol Blood Transfus. 2023.
- SEER Cancer Statistics Review 2024. NCI.
This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition.
